Successful outcome of a cirrhotic patient with postoperative haematuria treated with a single high dose of recombinant factor VIIa.
Recombinant factor VIIa (rfVIIa) has been widely used for the treatment and prevention of bleeding episodes in haemophiliacs with high-titre inhibitors. High single doses are the treatment of choice for joint and muscle bleeds in those patients. There are only a few reports on the value of rfVIIa in cirrhotic patients with haemostatic impairment but this drug can consistently correct the prothrombin time in these individuals. We report a case of a good response to a single high dose of rfVIIa in a patient with advanced liver disease who suffered from severe refractory postoperative haematuria.
Lucía
J F
JF
Department of Haematology, Hospital Miguel Servet Zaragoza. Spain.
Aguilar
C
C
Orna
E
E
Allepuz
C
C
Giralt
M
M
Carrasco
V
V
Simón
M A
MA
D005167:Factor VII / Q000008:administration & dosage*; D015942:Factor VIIa; D005355:Fibrosis / Q000150:complications* / Q000601:surgery; D006417:Hematuria / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy; D011994:Recombinant Proteins / Q000008:administration & dosage*; D016896:Treatment Outcome
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa